drugset
drugset / Trial / NCT05390476

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

NCT05390476 ↗

Phase 2 Unknown 126 enrolled wang shusen
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to explore and evaluate the efficacy of tucidinostat combined with metronomic capecitabine in the treatment of metastatic triple-negative breast cancer.

Timeline

Start
2022-08-01
Primary completion
2024-02-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 500 mg Oral
Subject Tucidinostat Small molecule 20 mg Oral

Indications

triple-negative breast carcinoma